An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
Signs the written informed consent form.
Female participants who are at least 18 years of age on the day of signing informed consent with.
ECOG of 0 or 1.
Life expectancy ≥ 3 months.
Other pathological types such as mucinous cancer, low-grade serous carcinoma, carcinosarcoma, sex cord stromal cell tumor, etc.
Presence of central nervous system (CNS) metastases or carcinomatous meningitis.
Subjects with uncontrollable pleural, pericardial, or peritoneal effusion requiring repeated drainage.
Patients with other active malignancies within 3 years prior to randomization.